Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Fortin

Showing results (141-150 of 343) with videos related to

Pageof 35
Sort By:
Advances in Experimental Medicine and Biology|April 30, 2009
High throughput solid phase parallel synthesis of macrocyclic peptidomimeticsE Marsault, H R Hoveyda, M L Peterson, et al.
ACS Medicinal Chemistry Letters|February 16, 2017
Optimization of 3-Pyrimidin-4-yl-oxazolidin-2-ones as Allosteric and Mutant Specific Inhibitors of IDH1Julian R Levell, Thomas Caferro, Gregg Chenail, et al.
Journal of Medicinal Chemistry|July 13, 2013
Identification of NVP-TNKS656: the use of structure-efficiency relationships to generate a highly potent, selective, and orally active tankyrase inhibitorMichael D Shultz, Atwood K Cheung, Christina A Kirby, et al.
Journal of Medicinal Chemistry|June 28, 2016
Allosteric Inhibition of SHP2: Identification of a Potent, Selective, and Orally Efficacious Phosphatase InhibitorJorge Garcia Fortanet, Christine Hiu-Tung Chen, Ying-Nan P Chen, et al.
Cancer Discovery|November 2, 2023
Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from HyperinsulinemiaAndreas Varkaris, Ermira Pazolli, Hakan Gunaydin, et al.
Nature|July 1, 2016
Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinasesYing-Nan P Chen, Matthew J LaMarche, Ho Man Chan, et al.
Journal of Medicinal Chemistry|September 10, 2020
Identification of TNO155, an Allosteric SHP2 Inhibitor for the Treatment of CancerMatthew J LaMarche, Michael Acker, Andreea Argintaru, et al.
Physical Review Letters|August 9, 2003
Measurements of the branching fractions and bounds on the charge asymmetries of charmless three-body charged B decaysB Aubert, R Barate, D Boutigny, et al.
Physical Review Letters|July 15, 2003
Observation of a narrow meson state decaying to D(+)(s)pi(0) at a mass of 2.32 GeV/c(2)B Aubert, R Barate, D Boutigny, et al.
Physical Review Letters|July 15, 2003
Measurement of the branching fraction, and bounds on the CP-violating asymmetries, of neutral B decays to D*+/- D-/+B Aubert, R Barate, D Boutigny, et al.
Pageof 35

Showing results (141-150 of 343) with videos related to

Sort By:
Pageof 35
Advances in Experimental Medicine and Biology|April 30, 2009
High throughput solid phase parallel synthesis of macrocyclic peptidomimeticsE Marsault, H R Hoveyda, M L Peterson, et al.
ACS Medicinal Chemistry Letters|February 16, 2017
Optimization of 3-Pyrimidin-4-yl-oxazolidin-2-ones as Allosteric and Mutant Specific Inhibitors of IDH1Julian R Levell, Thomas Caferro, Gregg Chenail, et al.
Journal of Medicinal Chemistry|July 13, 2013
Identification of NVP-TNKS656: the use of structure-efficiency relationships to generate a highly potent, selective, and orally active tankyrase inhibitorMichael D Shultz, Atwood K Cheung, Christina A Kirby, et al.
Journal of Medicinal Chemistry|June 28, 2016
Allosteric Inhibition of SHP2: Identification of a Potent, Selective, and Orally Efficacious Phosphatase InhibitorJorge Garcia Fortanet, Christine Hiu-Tung Chen, Ying-Nan P Chen, et al.
Cancer Discovery|November 2, 2023
Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from HyperinsulinemiaAndreas Varkaris, Ermira Pazolli, Hakan Gunaydin, et al.
Nature|July 1, 2016
Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinasesYing-Nan P Chen, Matthew J LaMarche, Ho Man Chan, et al.
Journal of Medicinal Chemistry|September 10, 2020
Identification of TNO155, an Allosteric SHP2 Inhibitor for the Treatment of CancerMatthew J LaMarche, Michael Acker, Andreea Argintaru, et al.
Physical Review Letters|August 9, 2003
Measurements of the branching fractions and bounds on the charge asymmetries of charmless three-body charged B decaysB Aubert, R Barate, D Boutigny, et al.
Physical Review Letters|July 15, 2003
Observation of a narrow meson state decaying to D(+)(s)pi(0) at a mass of 2.32 GeV/c(2)B Aubert, R Barate, D Boutigny, et al.
Physical Review Letters|July 15, 2003
Measurement of the branching fraction, and bounds on the CP-violating asymmetries, of neutral B decays to D*+/- D-/+B Aubert, R Barate, D Boutigny, et al.
Pageof 35